Learn How Businesses in the Healthcare Industry and Other Industries Involved in Collaborations with Competitors Can Plan to Minimize Uncertainty Resulting from the Withdrawal of the FTC/DOJ Healthcare Guidelines, from the DOJ’s Civil and Criminal Task Force on Healthcare Monopolies and Collusion, and from Other Recent DOJ and FTC Actions
The DOJ and FTC have recently taken significant actions to increase the antitrust scrutiny of healthcare companies overall and also other businesses involved in collaborations with competitors. This CLE webinar will assess these new developments and provide a concrete plan for how to minimize the uncertainty resulting from the withdrawal of the FTC/DOJ Healthcare Guidelines, from the DOJ’s Civil and Criminal Task Force on Healthcare Monopolies and Collusion, and from other recent DOJ and FTC actions.
The CLE webinar will also address:
- The reasons for and the implications of the withdrawal of the Healthcare Guidelines and the announcement of the DOJ Healthcare Task Force.
- Why there are significant implications extending beyond the healthcare industry.
- A simple approach to avoiding antitrust problems in the absence of FTC/DOJ Guidelines.
- How these changes have practically presented themselves in the deal context, contract negotiations, and day-to-day business strategy considerations for health plans, facilities, providers and others.
CLE Credit Available
Questions? Contact Baruch Kintisch, bkintisch@bakerlaw.com
*CLE credit is not available for viewing the recording of this webinar, which was presented and recorded on June 11, 2024.